MS Treatment Choice May Influence Depression Risk MS Treatment Choice May Influence Depression Risk

Patients with MS who receive rituximab are 28% less likely to develop depression, compared with patients who receive interferons. Depression also may influence adherence to interferons.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news